Guosheng Du

Dr. Guosheng Du


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LZLin Zhou
Lin Zhou
YZYang Zhao
Yang Zhao
LPLi-Chao Pan
Li-Chao Pan
JWJing Wang
Jing Wang
XSXian-Jie Shi
Xian-Jie Shi
QHQiang He
Qiang He
Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma

1 April 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
LZLin Zhou
Lin Zhou
LPLi-Chao Pan
Li-Chao Pan
YZYong-Gen Zheng
Yong-Gen Zheng
XZXin-Xue Zhang
Xin-Xue Zhang
ZLZhi-Jia Liu
Zhi-Jia Liu
QHQiang He
Qiang He
Background: Investigate immunoregulation and anti-tumor immunity of FoxP3+Tregs after treatment with rapamycin (RAPA/SRL) plus thymalfasin (Zadaxin) and Huaier extract (PS-T) in a hepatocellular carcinoma (HCC) rat model simulating HCC relapse after liver transplant (LT). Methods: We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining. The model rats were then treated with RAPA, Zadaxin, and PS-T. Immune status changes were analyzed by flow cytometry, and protein expression of Akt and mTOR was determined by western blotting. Cytokines were measured by ELISAs. Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02). Moreover, the levels of CD8+T cells were increased significantly to almost normal levels (P<0.05) in comparison with no SRL monotherapy protocols. Inhibitory cytokines were also decreased in accordance with FoxP3+Tregs. Significant decreases of IL-10 and TGF-β were observed after SRL-based therapy (P<0.01) in comparison with the other groups. Serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) levels were also decreased significantly (P<0.05). FoxP3+Tregs showed a negative correlation with CD8+ and CD4+/CD8+T cells and a positive correlation with AFP, and VEGF (P<0.05). Conclusions: SRL-based therapy reduces FoxP3+Tregs to decrease secreted inhibitory cytokines which may enhancement the viability and number of CD8+T cells to exert anti-tumor effects that are mainly mediated through the AKT-mTOR signaling pathway.

27 September 2021 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
YZYang Zhao
Yang Zhao
YLYu Liu
Yu Liu
LZLin Zhou
Lin Zhou
GDGuosheng Du
Guosheng Du
QHQiang He
Qiang He
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma

17 April 2026 in Hepatology Communications
Verified
Journal Article
Open access
LZLin Zhou
Lin Zhou
YZYang Zhao
Yang Zhao
JWJing Wang
Jing Wang
QCQing Chen
Qing Chen
YJYa-Nan Jia
Ya-Nan Jia
GDGuosheng Du
Guosheng Du
Background: Inducing transplant tolerance to achieve long-term graft survival without immunosuppression remains a central objective in liver transplantation. Methods: Using a rat liver transplantation model, we evaluated the effects of infusing rapamycin-modified tolerogenic dendritic cells (Rapa-tolDCs) on graft survival and tolerance induction. Underlying molecular and cellular mechanisms were investigated through activation and inhibition experiments to assess the generation, signaling pathways, and suppressive functions of regulatory T and B cell populations. Results: Infusion of Rapa-tolDCs induced donor-specific tolerance and markedly prolonged graft survival (median survival time of 65 days, maximum of 102 days). Mechanistically, Rapa-tolDCs, characterized by low expression of Siglec1 and Spp1, functioned independently of the PI3K–mTOR pathway and promoted the differentiation and proliferation of CD8+CD45RClow/− regulatory T cells (CD8+CD45RClow/− Tregs). We identified that these Tregs acquired MHC-II molecules from donor cells via trogocytosis, becoming immune chimeric cells that predominantly secreted interleukin-10 (IL-10) to mediate immune suppression. The generation of these MHC-II+CD8+ Tregs was regulated by the Wnt5a/Fzd4/RhoD signaling axis. Furthermore, elevated levels of Foxp3+ Tregs and IL-10+ Bregs were found to contribute to prolonged graft survival following Rapa-tolDC infusion. Conclusions: These findings delineate a complete mechanistic pathway from cell therapy to donor-specific tolerance and provide a foundational strategy for clinical tolerance induction and post-transplant immunomodulation.